Abstract:There is an urgent unmet medical need for novel human immunodeficiency virus type 1 (HIV-1) inhibitors that are effective against a variety of NNRTI-resistance mutations. We report our research efforts aimed at discovering a novel chemotype of anti-HIV-1 agents with improved potency against a variety of NNRTI-resistance mutations in this paper. Structural modifications of the lead K-5a2 led to the identification of a potent inhibitor 16c. 16c yielded highly potent anti-HIV-1 activities and improved resistance profiles compared with the approved drug etravirine. The co-crystal structure revealed the key role of the water networks surrounding the NNIBP for binding and for resilience against resistance mutations, while suggesting further extension of 16c toward the NNRTI-adjacent site as a lead development strategy. Furthermore, 16c demonstrated favorable pharmacokinetic and safety properties, suggesting the potential of 16c as a promising anti-HIV-1 drug candidate.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00268?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00268</a>.In vitro assay of anti-HIV activities in MT-4 cells, recombinant HIV-1 RT inhibitory assays, pharmacokinetic methods, acute toxicity experiment, and assay procedures for hERG activity (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00268/suppl_file/jm1c00268_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Combination of 2D and 3D-QSAR Studies on DAPY and DANA Derivatives As Potent HIV-1 NNRTIs

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Docking-based CoMFA and CoMSIA Studies on Naphthyl-Substituted Diarylpyrimidines As NNRTIs.

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

Docking and field-based QSAR studies of S-DABOs as HIV-1 reverse transcriptase inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Improving the Anti-Hiv-1 Activity and Solubility of Poorly Water-Soluble DAPYs by Heteroaromatic Replacement Strategy: from Naphthalene-Dapys to Quinoline-Dapys.

Revealing The Drug-Resistant Mechanism For Diarylpyrimidine Analogue Inhibitors Of Hiv-1 Reverse Transcriptase

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Ⅱ 3D-QSAR Study on 6-(1-naphthylmethyl)substituted Thymines

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Synthesis and Biological Evaluation of CHX-DAPYs As HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Druggability Modification Strategies of the Diarylpyrimidine‐type Non‐nucleoside Reverse Transcriptase Inhibitors